□□□□□□ HTA □□

□□□□

□□□□□□ (HTA) □□□□□□□

□) □□□□

□□□

HTA:□□

□□□

□	□□□□
2004	□□□□□□□□□□□□□□□□□□□□□□□□
2005	□□□□□□□□□□
2006	□□□□□□□□□□□□
2007	□□□□□□□□□□□□□□□
2008	ICER □□□□□□□□
2009	□□
2010	□□□□□□□□□□□□□□□□□□□
2011	□□□□□□□□□□□□□□□□
2012	□□□□□□□□□

HTA □□□□□□□□□□□□□□□□□□□□

□) □□□□□□□□□□□□□ (□□□□□□□□□) □□□□□□□□□□□□□

January, 2016, from http://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf
5. Velasco Garrido, M., Kristensen, F.B., Nielsen, C.P, and Busse, R. (2008).*Health technology assessment and health policy-making in Europe:Current status, challenges and potential.*Copenhagen:World Health Organization.Retrieved 6 January, 2016, from http://www.euro.who.int/__data/assets/pdf_file/0003/90426/E91922.pdf
6. Kleinjen, S., George, E., Goulden, S., et al. (2012).‘Relative effectiveness assessment of pharmaceuticals:similarities and differences in 29 jurisdictions’.*Value Health,* (15), 954-960.Retrieved 6 January, 2016, from http://www.valueinhealthjournal.com/article/S1098-3015(12)01609-9/pdf
7. Rawlins, M. (2014).‘Evidence, values, and decision-making.’ *International Journal of Technology Assessment in Health Care*, (30), 233-238.

□□□□

1. Ottawa Hospital Research Institute (2014).*Patient Decision Aids:Implementation Toolkit.*Retrieved 6 January, 2016, from http://decisionaid.ohri.ca/implement.html
2. Bandolier (2007).*Programme budgeting and marginal analysis*.Retrieved 6 January, 2016, from http://www.bandolier.org.uk/booth/glossary/PBMA.html